Copyright Reports & Markets. All rights reserved.

Global Liposomal Doxorubicin Market Insights and Forecast to 2027

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Liposomal Doxorubicin Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Liposomal Doxorubicin Market Size Growth Rate by Type
    • 1.4.2 5 ml
    • 1.4.3 10 ml
    • 1.2.4 25 ml
  • 1.3 Market by Application
    • 1.3.1 Global Liposomal Doxorubicin Market Size Growth Rate by Application
    • 1.3.2 Breast Cancer
    • 1.3.3 Liver Cancer
    • 1.3.4 Kidney Cancer
    • 1.3.5 Multiple Myeloma
    • 1.3.6 Ovarian Cancer
    • 1.3.7 Other
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Executive Summary

  • 2.1 Global Liposomal Doxorubicin Sales Estimates and Forecasts 2016-2027
  • 2.2 Global Liposomal Doxorubicin Revenue Estimates and Forecasts 2016-2027
  • 2.3 Global Liposomal Doxorubicin Revenue by Region: 2016 VS 2021 VS 2027
  • 2.4 Global Top Liposomal Doxorubicin Regions by Sales
    • 2.4.1 Global Top Liposomal Doxorubicin Regions by Sales (2016-2021)
    • 2.4.2 Global Top Liposomal Doxorubicin Regions by Sales (2022-2027)
  • 2.5 Global Top Liposomal Doxorubicin Regions by Revenue
    • 2.5.1 Global Top Liposomal Doxorubicin Regions by Revenue (2016-2021)
    • 2.5.2 Global Top Liposomal Doxorubicin Regions by Revenue (2022-2027)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa

3 Competition by Manufacturers

  • 3.1 Global Liposomal Doxorubicin Sales by Manufacturers
    • 3.1.1 Global Top Liposomal Doxorubicin Manufacturers by Sales (2016-2021)
    • 3.1.2 Global Top Liposomal Doxorubicin Manufacturers Market Share by Sales (2016-2021)
    • 3.1.3 Global Top 10 and Top 5 Companies by Liposomal Doxorubicin Sales in 2020
  • 3.2 Global Liposomal Doxorubicin Revenue by Manufacturers
    • 3.2.1 Global Top Liposomal Doxorubicin Manufacturers by Revenue (2016-2021)
    • 3.2.2 Global Top Liposomal Doxorubicin Manufacturers Market Share by Revenue (2016-2021)
    • 3.2.3 Global Top 10 and Top 5 Companies by Liposomal Doxorubicin Revenue in 2020
  • 3.3 Global Liposomal Doxorubicin Sales Price by Manufacturers
  • 3.4 Analysis of Competitive Landscape
    • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Liposomal Doxorubicin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.4.3 Global Liposomal Doxorubicin Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Liposomal Doxorubicin Sales by Type
    • 4.1.1 Global Liposomal Doxorubicin Historical Sales by Type (2016-2021)
    • 4.1.2 Global Liposomal Doxorubicin Forecasted Sales by Type (2022-2027)
    • 4.1.3 Global Liposomal Doxorubicin Sales Market Share by Type (2016-2027)
  • 4.2 Global Liposomal Doxorubicin Revenue by Type
    • 4.2.1 Global Liposomal Doxorubicin Historical Revenue by Type (2016-2021)
    • 4.2.2 Global Liposomal Doxorubicin Forecasted Revenue by Type (2022-2027)
    • 4.2.3 Global Liposomal Doxorubicin Revenue Market Share by Type (2016-2027)
  • 4.3 Global Liposomal Doxorubicin Price by Type
    • 4.3.1 Global Liposomal Doxorubicin Price by Type (2016-2021)
    • 4.3.2 Global Liposomal Doxorubicin Price Forecast by Type (2022-2027)

5 Market Size by Application

  • 5.1 Global Liposomal Doxorubicin Sales by Application
    • 5.1.1 Global Liposomal Doxorubicin Historical Sales by Application (2016-2021)
    • 5.1.2 Global Liposomal Doxorubicin Forecasted Sales by Application (2022-2027)
    • 5.1.3 Global Liposomal Doxorubicin Sales Market Share by Application (2016-2027)
  • 5.2 Global Liposomal Doxorubicin Revenue by Application
    • 5.2.1 Global Liposomal Doxorubicin Historical Revenue by Application (2016-2021)
    • 5.2.2 Global Liposomal Doxorubicin Forecasted Revenue by Application (2022-2027)
    • 5.2.3 Global Liposomal Doxorubicin Revenue Market Share by Application (2016-2027)
  • 5.3 Global Liposomal Doxorubicin Price by Application
    • 5.3.1 Global Liposomal Doxorubicin Price by Application (2016-2021)
    • 5.3.2 Global Liposomal Doxorubicin Price Forecast by Application (2022-2027)

6 North America

  • 6.1 North America Liposomal Doxorubicin Market Size by Type
    • 6.1.1 North America Liposomal Doxorubicin Sales by Type (2016-2027)
    • 6.1.2 North America Liposomal Doxorubicin Revenue by Type (2016-2027)
  • 6.2 North America Liposomal Doxorubicin Market Size by Application
    • 6.2.1 North America Liposomal Doxorubicin Sales by Application (2016-2027)
    • 6.2.2 North America Liposomal Doxorubicin Revenue by Application (2016-2027)
  • 6.3 North America Liposomal Doxorubicin Market Size by Country
    • 6.3.1 North America Liposomal Doxorubicin Sales by Country (2016-2027)
    • 6.3.2 North America Liposomal Doxorubicin Revenue by Country (2016-2027)
    • 6.3.3 U.S.
    • 6.3.4 Canada

7 Europe

  • 7.1 Europe Liposomal Doxorubicin Market Size by Type
    • 7.1.1 Europe Liposomal Doxorubicin Sales by Type (2017-2027)
    • 7.1.2 Europe Liposomal Doxorubicin Revenue by Type (2017-2027)
  • 7.2 Europe Liposomal Doxorubicin Market Size by Application
    • 7.2.1 Europe Liposomal Doxorubicin Sales by Application (2017-2027)
    • 7.2.2 Europe Liposomal Doxorubicin Revenue by Application (2017-2027)
  • 7.3 Europe Liposomal Doxorubicin Market Size by Country
    • 7.3.1 Europe Liposomal Doxorubicin Sales by Country (2017-2027)
    • 7.3.2 Europe Liposomal Doxorubicin Revenue by Country (2017-2027)
    • 7.3.3 Germany
    • 7.3.4 France
    • 7.3.5 U.K.
    • 7.3.6 Italy
    • 7.3.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific Liposomal Doxorubicin Market Size by Type
    • 8.1.1 Asia Pacific Liposomal Doxorubicin Sales by Type (2018-2027)
    • 8.1.2 Asia Pacific Liposomal Doxorubicin Revenue by Type (2018-2027)
  • 8.2 Asia Pacific Liposomal Doxorubicin Market Size by Application
    • 8.2.1 Asia Pacific Liposomal Doxorubicin Sales by Application (2018-2027)
    • 8.2.2 Asia Pacific Liposomal Doxorubicin Revenue by Application (2018-2027)
  • 8.3 Asia Pacific Liposomal Doxorubicin Market Size by Region
    • 8.3.1 Asia Pacific Liposomal Doxorubicin Sales by Region (2018-2027)
    • 8.3.2 Asia Pacific Liposomal Doxorubicin Revenue by Region (2018-2027)
    • 8.3.3 China
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 India
    • 8.3.7 Australia
    • 8.3.8 Taiwan
    • 8.3.9 Indonesia
    • 8.3.10 Thailand
    • 8.3.11 Malaysia
    • 8.3.12 Philippines

9 Latin America

  • 9.1 Latin America Liposomal Doxorubicin Market Size by Type
    • 9.1.1 Latin America Liposomal Doxorubicin Sales by Type (2019-2027)
    • 9.1.2 Latin America Liposomal Doxorubicin Revenue by Type (2019-2027)
  • 9.2 Latin America Liposomal Doxorubicin Market Size by Application
    • 9.2.1 Latin America Liposomal Doxorubicin Sales by Application (2019-2027)
    • 9.2.2 Latin America Liposomal Doxorubicin Revenue by Application (2019-2027)
  • 9.3 Latin America Liposomal Doxorubicin Market Size by Country
    • 9.3.1 Latin America Liposomal Doxorubicin Sales by Country (2019-2027)
    • 9.3.2 Latin America Liposomal Doxorubicin Revenue by Country (2019-2027)
    • 9.3.3 Mexico
    • 9.3.4 Brazil
    • 9.3.5 Argentina

6 Middle East and Africa

  • 6.1 Middle East and Africa Liposomal Doxorubicin Market Size by Type
    • 6.1.1 Middle East and Africa Liposomal Doxorubicin Sales by Type (2016-2027)
    • 6.1.2 Middle East and Africa Liposomal Doxorubicin Revenue by Type (2016-2027)
  • 6.2 Middle East and Africa Liposomal Doxorubicin Market Size by Application
    • 6.2.1 Middle East and Africa Liposomal Doxorubicin Sales by Application (2016-2027)
    • 6.2.2 Middle East and Africa Liposomal Doxorubicin Revenue by Application (2016-2027)
  • 6.3 Middle East and Africa Liposomal Doxorubicin Market Size by Country
    • 6.3.1 Middle East and Africa Liposomal Doxorubicin Sales by Country (2016-2027)
    • 6.3.2 Middle East and Africa Liposomal Doxorubicin Revenue by Country (2016-2027)
    • 6.3.3 Turkey
    • 6.3.4 Saudi Arabia
    • 6.3.5 U.A.E

11 Company Profiles

  • 11.1 Johnson & Johnson
    • 11.1.1 Johnson & Johnson Corporation Information
    • 11.1.2 Johnson & Johnson Overview
    • 11.1.3 Johnson & Johnson Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.1.4 Johnson & Johnson Liposomal Doxorubicin Product Description
    • 11.1.5 Johnson & Johnson Related Developments
  • 11.2 Sun Pharmaceutical
    • 11.2.1 Sun Pharmaceutical Corporation Information
    • 11.2.2 Sun Pharmaceutical Overview
    • 11.2.3 Sun Pharmaceutical Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.2.4 Sun Pharmaceutical Liposomal Doxorubicin Product Description
    • 11.2.5 Sun Pharmaceutical Related Developments
  • 11.3 CSPC
    • 11.3.1 CSPC Corporation Information
    • 11.3.2 CSPC Overview
    • 11.3.3 CSPC Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.3.4 CSPC Liposomal Doxorubicin Product Description
    • 11.3.5 CSPC Related Developments
  • 11.4 Kinyond
    • 11.4.1 Kinyond Corporation Information
    • 11.4.2 Kinyond Overview
    • 11.4.3 Kinyond Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.4.4 Kinyond Liposomal Doxorubicin Product Description
    • 11.4.5 Kinyond Related Developments
  • 11.5 Teva
    • 11.5.1 Teva Corporation Information
    • 11.5.2 Teva Overview
    • 11.5.3 Teva Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.5.4 Teva Liposomal Doxorubicin Product Description
    • 11.5.5 Teva Related Developments
  • 11.6 Fudan-Zhangjiang
    • 11.6.1 Fudan-Zhangjiang Corporation Information
    • 11.6.2 Fudan-Zhangjiang Overview
    • 11.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.6.4 Fudan-Zhangjiang Liposomal Doxorubicin Product Description
    • 11.6.5 Fudan-Zhangjiang Related Developments
  • 11.7 Zydus Cadila
    • 11.7.1 Zydus Cadila Corporation Information
    • 11.7.2 Zydus Cadila Overview
    • 11.7.3 Zydus Cadila Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.7.4 Zydus Cadila Liposomal Doxorubicin Product Description
    • 11.7.5 Zydus Cadila Related Developments
  • 11.8 TTY Biopharma
    • 11.8.1 TTY Biopharma Corporation Information
    • 11.8.2 TTY Biopharma Overview
    • 11.8.3 TTY Biopharma Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.8.4 TTY Biopharma Liposomal Doxorubicin Product Description
    • 11.8.5 TTY Biopharma Related Developments
  • 11.1 Johnson & Johnson
    • 11.1.1 Johnson & Johnson Corporation Information
    • 11.1.2 Johnson & Johnson Overview
    • 11.1.3 Johnson & Johnson Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.1.4 Johnson & Johnson Liposomal Doxorubicin Product Description
    • 11.1.5 Johnson & Johnson Related Developments

12 Value Chain and Sales Channels Analysis

  • 12.1 Liposomal Doxorubicin Value Chain Analysis
  • 12.2 Liposomal Doxorubicin Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Liposomal Doxorubicin Production Mode & Process
  • 12.4 Liposomal Doxorubicin Sales and Marketing
    • 12.4.1 Liposomal Doxorubicin Sales Channels
    • 12.4.2 Liposomal Doxorubicin Distributors
  • 12.5 Liposomal Doxorubicin Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

  • 13.1 Liposomal Doxorubicin Industry Trends
  • 13.2 Liposomal Doxorubicin Market Drivers
  • 13.3 Liposomal Doxorubicin Market Challenges
  • 13.4 Liposomal Doxorubicin Market Restraints

14 Key Findings in The Global Liposomal Doxorubicin Study

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Author Details

    Liposomal Doxorubicin market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Liposomal Doxorubicin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

    Segment by Type
    5 ml
    10 ml
    25 ml
    The classification of liposomal doxorubicin includes 5ml, 10 ml, etc. And the proportion of 10ml in 2020 is estimated about 88.77%.

    Segment by Application
    Breast Cancer
    Liver Cancer
    Kidney Cancer
    Multiple Myeloma
    Ovarian Cancer
    Other
    Liposomal doxorubicin is widely in breast cancer, liver cancer, kidney cancer, multiple myeloma, ovarian cancer, etc. the proportion of breast cancer in 2020 will be about 21.6%.

    By Company
    Johnson & Johnson
    Sun Pharmaceutical
    CSPC
    Kinyond
    Teva
    Fudan-Zhangjiang
    Zydus Cadila
    TTY Biopharma

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia

    Buy now